Calidi Biotherapeutics, Inc. (CLDI) Form 10-Q — May 14, 2026
Calidi Biotherapeutics reported a net loss of $4.1 million for the first quarter of 2026 and disclosed substantial doubt about its ability to continue as a going concern. The company cited recurring operating losses, negative cash flows, and an accumulated deficit of $145.7 million, stating it does not have sufficient cash to support operations for at least one year without raising additional capital. To address liquidity, Calidi completed a $6.0 million Confidentially Marketed Public Offering in March 2026, selling shares at $0.50 per unit. This follows a 1-for-12 reverse stock split implemented in August 2025, which reduced the share count and adjusted warrant exercise prices.
Key figures
- Total Debt
- 600000
- Cash Position
- 6631000
- Gross Proceeds
- 6000000
- Offering Price
- 0.5
- Shares Outstanding
- 19311625
- Warrant liability
- 67000
- Accumulated deficit
- 145729000
- Reverse split ratio
- 1:12
- Operating cash flow used
- 4100000
Price after filing
Close on the filing date to close N calendar days later (from $0.19). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.